Skip to main content

Table 1 Correlation between clinical parameters and early or late recurrence in 743 dataset

From: A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype

Clinical parameter N Early recurrence Late recurrence
Pvalue HR (95% CI) N (event) Pvalue HR (95% CI) N (event)
HER2 pos. vs. neg. 743 0.1378 1.36 (0.91 - 2.04) 207 0.7788 1.10 (0.57 - 2.13) 80
ER pos. vs. neg. 743 0.0048 0.63 (0.46 - 0.87) 207 0.5023 1.19 (0.72 - 1.97) 80
PR pos. vs. neg. 743 0.0004 0.61 (0.46 - 0.80) 207 0.1027 1.45 (0.93 - 2.28) 80
TNBC TN vs. others 743 0.0031 1.77 (1.21 - 2.59) 207 0.0974 0.61 (0.34 - 1.10) 80
Tumor size ≥2 cm vs. <2 cm 456 0.0008 1.91 (1.31 - 2.78) 114 0.3184 1.29 (0.78 - 2.12) 67
Grade Grade 3 vs. others 438 0.0038 1.87 (1.22 - 2.84) 110 0.0692 0.60 (0.35 - 1.04) 61
Age ≥50 vs. <50 457 0.9933 1.00 (0.69 - 1.44) 114 0.1144 0.67 (0.41 - 1.10) 66
  1. CI: confidence interval; ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; HR, hazard ratio; PR: progesterone receptor; TNBC: triple-negative breast cancer.